Gossamer Bio is trading 7.27% higher at $10.70, in a move more consistent with a broad stock-market recovery than a confirmed company-specific catalyst.
- No company-specific announcement explaining the November 9 move was confirmed; Gossamer Bio’s investor-relations page lists earlier items, including its September 9 seralutinib NDA announcement.
- Major indexes are sharply higher, and the supplied market context points to a broad recovery in stocks.